Atai Life Sciences appointed Sahil Kirpekar to serve as the company’s Chief Business Officer, effective immediately. Kirpekar joins atai after more than eight years at Otsuka Pharmaceutical, most recently as the Head of Business Development and Co-chair of the Global Business Development Committee. Prior to Otsuka, Kirpekar built and executed on commercial and market access strategies for biopharmaceutical companies globally as a strategy consultant at Double Helix Consulting. He also served as a market analyst for the World Health Organization and has co-founded a company building a drug delivery device focused on adherence.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ATAI:
- ‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $5
- Rising High: Exclusive talk with psychedelic biopharma firm Cybin
- atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
- atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
- atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology